These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

991 related articles for article (PubMed ID: 33441409)

  • 1. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 2. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes.
    Lesniak NA; Schubert AM; Sinani H; Schloss PD
    mSphere; 2021 May; 6(3):. PubMed ID: 33952668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
    Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
    mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
    Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
    Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Osmotic Laxative Renders Mice Susceptible to Prolonged Clostridioides difficile Colonization and Hinders Clearance.
    Tomkovich S; Taylor A; King J; Colovas J; Bishop L; McBride K; Royzenblat S; Lesniak NA; Bergin IL; Schloss PD
    mSphere; 2021 Oct; 6(5):e0062921. PubMed ID: 34585964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
    Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
    Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
    Johnson SW; Brown SV; Priest DH
    Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of vancomycin-resistant enterococci (VRE) in stool specimens submitted for Clostridium difficile toxin testing.
    Özsoy S; İlki A
    Braz J Microbiol; 2017; 48(3):489-492. PubMed ID: 28389190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
    Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
    Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Significance of Toxigenic Clostridioides difficile Growth in Stool Cultures during the Era of Nonculture Methods for the Diagnosis of C. difficile Infection.
    Lee CC; Lee JC; Chiu CW; Tsai PJ; Ko WC; Hung YP
    Microbiol Spectr; 2021 Oct; 9(2):e0079921. PubMed ID: 34668727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation.
    Gonzales-Luna AJ; Spinler JK; Oezguen N; Khan MAW; Danhof HA; Endres BT; Alam MJ; Begum K; Lancaster C; Costa GP; Savidge TC; Hurdle JG; Britton R; Garey KW
    Anaerobe; 2021 Aug; 70():102387. PubMed ID: 34044101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
    Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW
    Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of oral vancomycin treatment duration on rate of
    Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
    Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
    Cannon K; Byrne B; Happe J; Wu K; Ward L; Chesnel L; Louie T
    J Antimicrob Chemother; 2017 Dec; 72(12):3453-3461. PubMed ID: 28927227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 17. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole.
    Abujamel T; Cadnum JL; Jury LA; Sunkesula VC; Kundrapu S; Jump RL; Stintzi AC; Donskey CJ
    PLoS One; 2013; 8(10):e76269. PubMed ID: 24098459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
    Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
    Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
    van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
    J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
    Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.